Difference between revisions of "ICRP Glossary"

From ICRPaedia
Jump to navigation Jump to search
Line 16: Line 16:
 
*[[Active (red) bone marrow]]
 
*[[Active (red) bone marrow]]
  
*[[Activity median thermodynamic diameter (AMTD)]]
+
*[[Activity median thermodynamic diameter ]]
  
*[[Activity, A]]
+
*[[Activity]]
  
 
*[[Acute Exposure]]
 
*[[Acute Exposure]]
Line 26: Line 26:
 
*[[Adventitious Source]]
 
*[[Adventitious Source]]
  
*[[Aerodynamic diameter (dae)]]
+
*[[Aerodynamic diameter ]]
  
 
*[[Air sampling]]
 
*[[Air sampling]]
Line 32: Line 32:
 
*[[Air-kerma rate constant]]
 
*[[Air-kerma rate constant]]
  
*[[Air-kerma rate constant (Γδ)]]
+
*[[Air-kerma rate constant ]]
  
 
*[[Air-kerma, entrance surface]]
 
*[[Air-kerma, entrance surface]]
  
*[[Air-kerma, incident (Ki)]]
+
*[[Air-kerma, incident]]
  
*[[Air-kerma, product (PKA)]]
+
*[[Air-kerma, product]]
  
 
*[[Alimentary tract]]
 
*[[Alimentary tract]]
  
*[[Alimentary tract transfer factor, fA]]
+
*[[Alimentary tract transfer factor]]
  
 
*[[Alpha decay]]
 
*[[Alpha decay]]
  
*[[Alveolar-interstitial region, AI]]
+
*[[Alveolar-interstitial region]]
  
 
*[[Angiogenesis]]
 
*[[Angiogenesis]]
Line 76: Line 76:
 
*[[Background dose (rate)]]
 
*[[Background dose (rate)]]
  
*[[Backscatter Factor (B)]]
+
*[[Backscatter Factor ]]
  
 
*[[Basal cell]]
 
*[[Basal cell]]
Line 84: Line 84:
 
*[[Benthic]]
 
*[[Benthic]]
  
*[[Best Available Techniques (BAT)]]
+
*[[Best Available Techniques]]
  
 
*[[Beta-minus decay]]
 
*[[Beta-minus decay]]
Line 150: Line 150:
 
*[[Colony]]
 
*[[Colony]]
  
*[[Committed effective dose, E(τ)]]
+
*[[Committed effective dose]]
  
 
*[[Commodity]]
 
*[[Commodity]]
Line 156: Line 156:
 
*[[Complex tissues]]
 
*[[Complex tissues]]
  
*[[Computed tomography dose index, CTDI]]
+
*[[Computed tomography dose index]]
  
 
*[[Conditional renewing (complex or flexible) tissues]]
 
*[[Conditional renewing (complex or flexible) tissues]]
Line 186: Line 186:
 
*[[Critical group]]
 
*[[Critical group]]
  
*[[Curie, Ci]]
+
*[[Curie]]
  
 
*[[Cytokines]]
 
*[[Cytokines]]
Line 234: Line 234:
 
*[[Dose criteria]]
 
*[[Dose criteria]]
  
*[[Dose equivalent in an organ or tissue, HT,Q]]
+
*[[Dose equivalent in an organ or tissue]]
  
 
*[[Dose limit]]
 
*[[Dose limit]]
  
*[[Dose Modifying Factor (DMF)]]
+
*[[Dose Modifying Factor]]
  
*[[Dose per unit intake, DPUI]]
+
*[[Dose per unit intake]]
  
 
*[[Dose rate]]
 
*[[Dose rate]]
  
*[[Dose rate effectiveness factor, DREF]]
+
*[[Dose rate effectiveness factor]]
  
 
*[[Dosemeter/dosimeter]]
 
*[[Dosemeter/dosimeter]]
Line 250: Line 250:
 
*[[Dose-rate effect]]
 
*[[Dose-rate effect]]
  
*[[Dose–response function (DRF)]]
+
*[[Dose–response function ]]
  
 
*[[Dose-threshold]]
 
*[[Dose-threshold]]
Line 264: Line 264:
 
*[[Early normal tissue responses]]
 
*[[Early normal tissue responses]]
  
*[[Effect Dose 50 (ED50)]]
+
*[[Effect Dose 50 ]]
  
*[[Effective charge number, Z*]]
+
*[[Effective charge number]]
  
*[[Effective dose equivalent, HE]]
+
*[[Effective dose equivalent]]
  
*[[Effective half-life (Teff)]]
+
*[[Effective half-life]]
  
 
*[[Electron-capture decay]]
 
*[[Electron-capture decay]]
Line 302: Line 302:
 
*[[Equity]]
 
*[[Equity]]
  
*[[Equivalent dose (HT)]]
+
*[[Equivalent dose]]
  
 
*[[Erythropoietin]]
 
*[[Erythropoietin]]
Line 361: Line 361:
  
  
*[[Galactic cosmic radiation (GCR)]]
+
*[[Galactic cosmic radiation]]
  
 
*[[Gamma ray]]
 
*[[Gamma ray]]
Line 387: Line 387:
 
*[[Habitual nose breather]]
 
*[[Habitual nose breather]]
  
*[[Half-life, physical (T1/2)]]
+
*[[Half-life, physical]]
  
 
*[[Hazard]]
 
*[[Hazard]]
Line 397: Line 397:
 
*[[Hierarchical tissues]]
 
*[[Hierarchical tissues]]
  
*[[High level waste, HLW]]
+
*[[High level waste]]
  
 
*[[Hormones]]
 
*[[Hormones]]
  
*[[Human Respiratory Tract Model (HRTM)]]
+
*[[Human Respiratory Tract Model ]]
  
 
*[[Hyperbaric oxygen]]
 
*[[Hyperbaric oxygen]]
Line 439: Line 439:
 
*[[Informed Consent]]
 
*[[Informed Consent]]
  
*[[Ingestion exposure planning zone,  IEPZ]]
+
*[[Ingestion exposure planning zone]]
  
 
*[[Inhalability]]
 
*[[Inhalability]]
Line 451: Line 451:
 
*[[Institutional control]]
 
*[[Institutional control]]
  
*[[Intermediate level waste, ILW]]
+
*[[Intermediate level waste]]
  
 
*[[Internal conversion electron]]
 
*[[Internal conversion electron]]
Line 487: Line 487:
 
==== K ====
 
==== K ====
  
*[[K, Kp index]]
+
*[Kp index]]
  
*[[Kerma-area product (KAP)]]
+
*[[Kerma-area product]]
  
 
==== L ====
 
==== L ====
  
*[[Late effect, delayed effect]]
+
*[[Late effect/delayed effect]]
  
 
*[[Latent time/period or latency interval]]
 
*[[Latent time/period or latency interval]]
Line 507: Line 507:
 
*[[Lineal energy]]
 
*[[Lineal energy]]
  
*[[Linear no-threshold (LNT) hypothesis]]
+
*[[Linear no-threshold hypothesis]]
  
*[[Linear-non-threshold (LNT) model]]
+
*[[Linear-non-threshold model]]
  
*[[Low Earth orbit (LEO)]]
+
*[[Low Earth orbit]]
  
*[[Low level waste, LLW]]
+
*[[Low level waste]]
  
 
*[[Low toxicity alpha emitter]]
 
*[[Low toxicity alpha emitter]]
Line 535: Line 535:
 
*[[Mendelian diseases]]
 
*[[Mendelian diseases]]
  
*[[Minimum significant activity (MSA)]]
+
*[[Minimum significant activity]]
  
 
*[[Mitigation]]
 
*[[Mitigation]]
Line 553: Line 553:
 
*[[Natural environment]]
 
*[[Natural environment]]
  
*[[Naturally occurring radioactive material (NORM)]]
+
*[[Naturally occurring radioactive material]]
  
 
*[[Necrosis]]
 
*[[Necrosis]]
Line 563: Line 563:
 
*[[Non-maleficence]]
 
*[[Non-maleficence]]
  
*[[Non-sphericity parameter (η)]]
+
*[[Non-sphericity parameter]]
  
 
*[[Nuclear track detectors]]
 
*[[Nuclear track detectors]]
Line 577: Line 577:
 
*[[Oedema]]
 
*[[Oedema]]
  
*[[Operational intervention level, OIL]]
+
*[[Operational intervention level]]
  
 
*[[Operational monitoring]]
 
*[[Operational monitoring]]
  
*[[Optically stimulated luminescence (OSL)  dosimeters]]
+
*[[Optically stimulated luminescence dosimeters]]
  
 
*[[Optimisation]]
 
*[[Optimisation]]
Line 591: Line 591:
 
==== P ====
 
==== P ====
  
*[[Particle radiance, Φ ̇Ω]]
+
*[[Particle radiance]]
  
 
*[[Patient]]
 
*[[Patient]]
Line 601: Line 601:
 
*[[Pelagic]]
 
*[[Pelagic]]
  
*[[Percutaneous coronary intervention (PCI)]]
+
*[[Percutaneous coronary intervention]]
  
 
*[[Pericarditis]]
 
*[[Pericarditis]]
Line 655: Line 655:
 
*[[Protective action]]
 
*[[Protective action]]
  
*[[Protective action guide, PAG]]
+
*[[Protective action guide]]
  
 
*[[Protective clothing]]
 
*[[Protective clothing]]
Line 683: Line 683:
 
*[[Radiation protection programme]]
 
*[[Radiation protection programme]]
  
*[[Radiation safety officer, RSO]]
+
*[[Radiation safety officer]]
  
 
*[[Radiation Source]]
 
*[[Radiation Source]]
Line 691: Line 691:
 
*[[Radioactive contamination]]
 
*[[Radioactive contamination]]
  
*[[Radioactive dispersion device (RDD)]]
+
*[[Radioactive dispersion device]]
  
 
*[[Radioactive source]]
 
*[[Radioactive source]]
Line 777: Line 777:
 
*[[Rigidity threshold]]
 
*[[Rigidity threshold]]
  
*[[Rigidity, R]]
+
*[[Rigidity]]
  
 
*[[Risk constraint]]
 
*[[Risk constraint]]
  
*[[Roentgen, R]]
+
*[[Roentgen]]
  
 
*[[Routine monitoring]]
 
*[[Routine monitoring]]
Line 843: Line 843:
 
*[[Subcutaneous tissue]]
 
*[[Subcutaneous tissue]]
  
*[[Substantial radiation dose level (SRDL)]]
+
*[[Substantial radiation dose level]]
  
 
*[[Supervised Area]]
 
*[[Supervised Area]]
Line 859: Line 859:
 
*[[Target cell]]
 
*[[Target cell]]
  
*[[Target tissue (T)]]
+
*[[Target tissue]]
  
 
*[[Task-related monitoring]]
 
*[[Task-related monitoring]]
Line 893: Line 893:
 
*[[Transfer compartment]]
 
*[[Transfer compartment]]
  
*[[Transforming growth factor (TGF)]]
+
*[[Transforming growth factor]]
  
 
*[[Transit cells]]
 
*[[Transit cells]]
Line 935: Line 935:
 
*[[Weighted CTDI]]
 
*[[Weighted CTDI]]
  
*[[Whole body counter, WBC]]
+
*[[Whole body counter]]
  
 
*[[Wisdom]]
 
*[[Wisdom]]

Revision as of 15:48, 9 April 2019

A

B

C

D

E

F

G

H

I

J

K

  • [Kp index]]

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y